

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Mepolizumab for treating severe
eosinophilic asthma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

| |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No equalities issues identified |

| |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| None |

| |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No |

| |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? |
|--|

| |
|---|
| If so, what are the barriers to, or difficulties with, access for the specific group? |
| No |

| |
|---|
| 5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No |

| |
|---|
| 6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| NA |

| |
|---|
| 7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| NA |

Approved by Associate Director (name): ...Janet Robertson.....

Date: 11 December 2020